Physician profile
Min Yoo
NPI 1164817557
$3,206.54
in general payments reported to CMS, 2019-2025
15 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,232 · 2020: $368 · 2023: $95.07 · 2024: $365 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,315.51 | 2019 | |
| Abbott Laboratories | $319.98 | 2019-2020 | |
| Stimwave Technologies Incorporated | $285.54 | 2019-2020 | |
| Boston Scientific Corporation | $185.13 | 2019 | |
| Averitas Pharma INC. | $153.33 | 2024-2025 | Qutenza |
| Pacira Therapeutics, INC. | $147.49 | 2019 | |
| Revance Therapeutics, INC. | $121.93 | 2024 | Daxxify |
| Pharmacosmos Therapeutics INC. | $106.93 | 2024 | Monoferric |
| Mml US, INC. | $53.52 | 2023 | Reactiv8 |
| Zimmer Biomet Holdings, INC. | $43.75 | 2024 | Biocue |
| Merz Pharmaceuticals, LLC | $41.55 | 2023 | Xeomin |
| Novartis Pharmaceuticals Corporation | $28.76 | 2024-2025 | |
| Canon Medical Systems USA, INC. | $20.96 | 2024 | General Device(S) |
| Hydrocision, INC. | $18.90 | 2024 | Tenjet |
| Depuy Synthes Sales INC. | $16.28 | 2024 | Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.